Oral Steroid Dosing for Moderate to Severe Crohn's Disease

Initial Dosing Regimen

The Canadian Association of Gastroenterology strongly recommends administering prednisone 40-60 mg/day orally as the standard induction dose for moderate to severe Crohn's disease 1, 2, 3
The American Gastroenterological Association suggests that prednisone 40-60 mg/day is used as first-line therapy for moderate to severe disease, particularly when disease extends beyond the right colon or when severity is clearly in the moderate-to-severe range 1, 4

The European Crohn’s and Colitis Organisation recommends reserving budesonide 9 mg/day for mild to moderate disease limited to the ileum and/or right colon only 2, 3
Escalate from budesonide to prednisone 40-60 mg/day if patients with moderate disease fail to respond to budesonide after 4-8 weeks, as conventional steroids are more effective than budesonide (meta-analysis showed budesonide was significantly less effective with RR 0.85, 95% CI 0.75-0.97) 3, 4

Evaluate symptomatic response between 2-4 weeks after starting prednisone to determine if therapy modification is needed—this is a strong recommendation from the American Gastroenterological Association 1, 2, 3
Expect mean time to symptomatic remission of approximately 20-41 days based on clinical trial data 4
Arrange earlier assessment (closer to 2 weeks) for severe disease, while patients with more moderate symptoms can be assessed at 4 weeks 4

Avoid corticosteroids or use with extreme caution in patients with poorly controlled diabetes, as recommended by the American Diabetes Association 4
Avoid corticosteroids or use with extreme caution in patients with a history of steroid-induced psychosis or depression, as recommended by the American Psychiatric Association 4
Provide prophylaxis by starting all patients on adequate calcium and vitamin D when initiating corticosteroids to prevent bone loss, as recommended by the National Osteoporosis Foundation 4

Prednisone induces remission in 60-83% of patients with moderate to severe Crohn's disease, according to the Crohn's & Colitis Foundation 6
Corticosteroids are significantly more effective than placebo (RR 1.99, 95% CI 1.51-2.64) but are associated with higher adverse event rates (RR 4.89, 95% CI 1.98-12.07), as reported by the American Gastroenterological Association 4

Switch to IV methylprednisolone 40-60 mg/day (typically 40 mg every 8 hours) if disease severity requires hospitalization, as recommended by the Society of Hospital Medicine 1, 2, 5
Evaluate response to IV therapy within 1 week to determine if therapy modification is needed, as recommended by the American Gastroenterological Association 1, 5

Do NOT use oral corticosteroids for maintenance therapy—this is a strong recommendation against their use for maintaining remission in Crohn's disease of any severity, as stated by the American Gastroenterological Association 1, 2, 3, 5
Plan for steroid-sparing maintenance therapy in patients who respond to induction, using thiopurines, methotrexate, or anti-TNF biologics, as recommended by the Crohn's & Colitis Foundation 5, 6
Consider anti-TNF therapy (infliximab, adalimumab) for patients who fail to achieve remission with corticosteroids, as this is a strong recommendation supported by high-quality evidence from the American Gastroenterological Association 1, 6